Literature DB >> 29742812

Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.

Kazi Abdus Salam1,2, Richard Y Wang1, Teresa Grandinetti1, Valeria De Giorgi1, Harvey J Alter1, Robert D Allison1.   

Abstract

Erythrocytes bind circulating immune complexes (ICs) and facilitate IC clearance from the circulation. Chronic hepatitis C virus (HCV) infection is associated with IC-related disorders. In this study, we investigated the kinetics and mechanism of HCV and HCV-IC binding to and dissociation from erythrocytes. Cell culture-produced HCV was mixed with erythrocytes from healthy blood donors, and erythrocyte-associated virus particles were quantified. Purified complement proteins, complement-depleted serum, and complement receptor antibodies were used to investigate complement-mediated HCV-erythrocyte binding. Purified HCV-specific immunoglobulin G (IgG) from a chronic HCV-infected patient was used to study complement-mediated HCV-IC/erythrocyte binding. Binding of HCV to erythrocytes increased 200- to 1,000-fold after adding complement active human serum in the absence of antibody. Opsonization of free HCV occurred within 10 minutes, and peak binding to erythrocytes was observed at 20-30 minutes. Complement protein C1 was required for binding, whereas C2, C3, and C4 significantly enhanced binding. Complement receptor 1 (CR1, CD35) antibodies blocked the binding of HCV to erythrocytes isolated from chronically infected HCV patients and healthy blood donors. HCV-ICs significantly enhanced complement-mediated binding to erythrocytes compared to unbound HCV. Dissociation of complement-opsonized HCV from erythrocytes depended on the presence of Factor I. HCV released by Factor I bound preferentially to CD19+ B cells compared to other leukocytes.
Conclusion: These results demonstrate that complement mediates the binding of free and IC-associated HCV to CR1 on erythrocytes and provide a mechanistic rationale for investigating the differential phenotypic expression of HCV-IC-related disease. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29742812      PMCID: PMC6226377          DOI: 10.1002/hep.30087

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  Investigation of residual hepatitis C virus in presumed recovered subjects.

Authors:  Kei Fujiwara; Robert D Allison; Richard Y Wang; Patricia Bare; Kentaro Matsuura; Cathy Schechterly; Krishna Murthy; Francesco M Marincola; Harvey J Alter
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

2.  In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.

Authors:  Philip Meuleman; Jens Bukh; Lieven Verhoye; Ali Farhoudi; Thomas Vanwolleghem; Richard Y Wang; Isabelle Desombere; Harvey Alter; Robert H Purcell; Geert Leroux-Roels
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

3.  C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.

Authors:  S W Tas; L B Klickstein; S F Barbashov; A Nicholson-Weller
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

Review 4.  Hepatitis C virus and liver transplantation: where do we stand?

Authors:  Patrizia Burra; Eleonora De Martin; Alberto Zanetto; Marco Senzolo; Francesco Paolo Russo; Giacomo Zanus; Stefano Fagiuoli
Journal:  Transpl Int       Date:  2015-08-11       Impact factor: 3.782

5.  Immunochemical and biomolecular studies of circulating immune complexes isolated from patients with acute and chronic hepatitis C virus infection.

Authors:  D Sansonno; A R Iacobelli; V Cornacchiulo; G Lauletta; M A Distasi; P Gatti; F Dammacco
Journal:  Eur J Clin Invest       Date:  1996-06       Impact factor: 4.686

6.  Complement mediates the binding of HIV to erythrocytes.

Authors:  Eliska Horakova; Olivier Gasser; Salima Sadallah; Jameel M Inal; Guillaume Bourgeois; Ingrid Ziekau; Thomas Klimkait; Jürg A Schifferli
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

7.  Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma.

Authors:  Scott W Biggins; Kiran M Bambha; Norah A Terrault; John Inadomi; Stephen Shiboski; Jennifer L Dodge; Jane Gralla; Hugo R Rosen; John P Roberts
Journal:  Liver Transpl       Date:  2012-12       Impact factor: 5.799

8.  Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes.

Authors:  M Hijikata; Y K Shimizu; H Kato; A Iwamoto; J W Shih; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry).

Authors:  Manuel Ramos-Casals; Sandra Muñoz; Francisco Medina; Luis-Javier Jara; José Rosas; Jaime Calvo-Alen; Pilar Brito-Zerón; Xavier Forns; Jose-Maria Sánchez-Tapias
Journal:  J Rheumatol       Date:  2009-04-15       Impact factor: 4.666

10.  Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.

Authors:  G D Ross; S L Newman; J D Lambris; J E Devery-Pocius; J A Cain; P J Lachmann
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more
  3 in total

1.  Different profiles of neurocognitive impairment in patients with hepatitis B and C virus infections.

Authors:  Chun-Hsiang Tan; Meng-Chia Chang; Wei-Fang Tsai; Wan-Long Chuang; Jee-Fu Huang; Zu-Yau Lin; Chia-Yen Dai; Ming-Lun Yeh; Chi-Ting Li; Rwei-Ling Yu
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

Review 2.  "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma.

Authors:  Astha Malik; Unmesha Thanekar; Surya Amarachintha; Reena Mourya; Shreya Nalluri; Alexander Bondoc; Pranavkumar Shivakumar
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 5.738

3.  COVID-19 and the Coombs test.

Authors:  Jeanne E Hendrickson; Christopher A Tormey
Journal:  Blood       Date:  2020-08-06       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.